Here's Why You Should Retain McKesson Stock in Your Portfolio Now

McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism led by a decent first-quarter fiscal 2025 performance and improving demand for healthcare are expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.In the past one year, MCK shares have gained 36.1% compared with the industry’s rise of 3.5%. The S&P 500 has gained 27.1% in the same time frame.The renowned healthcare ...